Jupiter Neurosciences Inc. (NASDAQ:JUNS) is a clinical-stage pharmaceutical company developing drugs to treat neuroinflammation, focusing on central nervous system diseases. The company's two-prong approach may hold the key to success in the biotech industry, which is often challenging. Jupiter Neurosciences is working to crack the code on biotech success with its innovative approach.
Read full articleJune 13, 2025 • By Quantum BioPharma
Quantum BioPharma Ltd. intends to declare a special dividend consisting of Contingent Value Rights (CVRs) to holders of its Class B Subordinate Voting Shares. Each CVR will entitle the holder to receive a pro-rata portion of 10%-50% of the net proceeds from the company's litigation against CIBC World Markets, RBC Dominion Securities, and others, which seeks damages over $700 million for alleged stock price manipulation and spoofing. The record date and payout percentage will be determined later. The CVRs are subject to necessary approvals and regulatory requirements. Quantum BioPharma is a biopharmaceutical company focused on developing innovative assets and biotech solutions for neurodegenerative and metabolic disorders.
June 13, 2025 • By https://www.mindbodygreen.com/wc/alexandra-engler
The article discusses the formation of wrinkles, particularly in areas with thin skin, and provides tips on how to treat them. Wrinkles tend to develop faster in areas around the eyes, hands, and neck due to various factors such as collagen breakdown, environmental aggressors, and posture. To treat wrinkles, the article recommends using products specifically designed for each area, such as eye creams for the eye area, hand creams for the hands, and neck creams for the neck. It also suggests looking for ingredients like hyaluronic acid, caffeine, peptides, retinol, and antioxidants, which can help plump, ease, and smooth out wrinkles. Additionally, the article emphasizes the importance of wearing sunscreen to prevent wrinkles and notes that developing wrinkles is a natural part of life, but taking care of one's skin can help reduce their formation.
June 13, 2025 • By ITM Isotope Technologies Munich SE
ITM Isotope Technologies Munich SE will present further analysis from its Phase 3 COMPETE trial at the Society of Nuclear Medicine and Molecular Imaging annual meeting. The trial evaluated 177Lu-edotreotide in patients with gastroenteropancreatic neuroendocrine tumors and met its primary endpoint, demonstrating improved progression-free survival. The data will be presented in an oral presentation and a Satellite Symposium, which will feature an overview of the treatment landscape and perspectives on dosimetry standardization. ITM's Chief Medical Officer, Dr. Celine Wilke, will also participate in an Entrepreneur's Panel. The company will have a booth at the conference, providing information on its innovations in radiopharmaceutical therapy and pipeline.
June 13, 2025
The article provides a brief overview of the current market performance of several companies, including Tesla (+2.47%), Nissan (+0.81%), Cleveland-Cliffs (-0.07%), Nucor (+2.14%), and D-Wave Quantum (-4.59%). It also mentions upcoming IPOs and secondary offerings, as well as exclusive analysis and ratings, although the details of these are locked and require further access.
June 13, 2025
XtalPi, a life sciences and new materials R&D platform, has acquired Liverpool ChiroChem (LCC), a pioneer in automated chiral chemistry technologies. The merger will enhance XtalPi's ability to explore and synthesize novel chemical space with speed and precision, accelerating innovation for pharmaceutical, materials, and specialty chemical applications. LCC's expertise in chiral chemistry will broaden XtalPi's accessible chemical space, propelling the discovery of next-generation therapeutics and materials. The combined entity will operate labs, automation systems, and AI infrastructure in the US, Europe, and Asia, offering clients enhanced operational flexibility and security.
June 13, 2025 • By Kizito Makoye
The UN Ocean Conference has concluded with a flurry of voluntary commitments and political declarations to conserve marine biodiversity. The Kunming-Montreal Global Biodiversity Framework sets out 23 urgent action targets to be achieved by 2030, including protecting and restoring ecosystems, halting species extinction, and mitigating climate impacts. However, funding gaps and harmful subsidies remain significant challenges, with speakers warning that ambition alone is not enough. The private sector needs to move beyond viewing biodiversity as a philanthropic cause and invest in nature-based solutions. The upcoming COP17 summit in 2026 will be a crucial moment to assess progress and reinforce linkages with the new High Seas Treaty. Officials are urging all parties to submit their updated plans and reports by February 2026, as the clock is ticking to meet the 2030 biodiversity targets.
June 13, 2025 • By Transgene S.A.
Transgene, a biotech company, announced its management team will meet with investors and scientists to discuss its virus-based immunotherapies for cancer treatment. The company recently presented positive clinical data on its individualized neoantigen cancer vaccine, TG4050, at the American Society of Clinical Oncology Annual Meeting. Transgene's lead asset, TG4050, has demonstrated proof of principle in patients with head and neck cancers. The company's portfolio includes other viral-vector-based immunotherapies, and it conducts innovative discovery and preclinical work to develop novel viral vector-based modalities.
June 13, 2025 • By MarketBeat News
Here's a concise summary of the article: Seven biotech stocks to watch are Thermo Fisher Scientific, Kazia Therapeutics, Danaher, AbbVie, Veeva Systems, United Therapeutics, and Vertex Pharmaceuticals. These companies had the highest dollar trading volume in the last few days. They develop medical therapies, diagnostic tools, and other health-related biotechnology innovations. - Thermo Fisher Scientific (NYSE: TMO) traded up $3.05 to $417.59 with a market cap of $157.64 billion. - Kazia Therapeutics (KZIA) traded up $3.94 to $9.20 with a 12-month low of $2.86. - Danaher (DHR) traded up $1.81 to $204.43 with a market cap of $146.30 billion. - AbbVie (NYSE: ABBV) traded up $2.45 to $191.95 with a market cap of $339.06 billion. - Veeva Systems (NYSE: VEEV) traded up $0.65 to $284.78 with a market cap of $46.33 billion. - United Therapeutics (NASDAQ: UTHR) traded up $2.01 to $283.37 with a market cap of $12.78 billion. - Vertex Pharmaceuticals (VRTX) traded up $5.81 to $457.33 with a market cap of $117.44 billion. These companies invest heavily in research and development, and their stock prices can be volatile due to clinical trial results, regulatory approvals, and scientific breakthroughs.
June 13, 2025 • By MarketBeat News
Nicola Shepherd, an insider at The Biotech Growth Trust PLC, purchased 500 shares of the company's stock on June 10th at an average price of GBX 771 ($10.50) per share, totaling £3,855 ($5,248.47). The company's stock opened at GBX 766 ($10.43) on Friday, with a 50-day moving average of GBX 713.33 and a 200-day moving average of GBX 799.08. The Biotech Growth Trust PLC has a market cap of £218.84 million and a 52-week range of GBX 612.70 ($8.34) to GBX 1,068.36 ($14.55).
June 13, 2025 • By MarketBeat News
HC Wainwright issued Q2 2025 earnings estimates for Moleculin Biotech, forecasting a loss of $0.41 per share. The firm has a "Buy" rating and a $4.00 price target. Consensus estimates for the full year are a loss of $7.98 per share. Moleculin Biotech last reported a quarterly loss of $0.69 per share, beating estimates. The stock has a 1-year low of $0.40 and a high of $4.90. A hedge fund, Armistice Capital LLC, raised its stake in the company by 293.6% in the first quarter, owning approximately 8.93% of the company's stock. Moleculin Biotech is a clinical-stage pharmaceutical company focused on developing drug candidates for cancer and virus treatments.
June 13, 2025 • By MarketBeat News
Oncolytics Biotech Inc. (NASDAQ:ONCY) has received an average rating of "Moderate Buy" from four brokerages. The average 1-year target price is $4.33. Analysts have commented on the stock, with Royal Bank of Canada decreasing its target price to $5.00 and HC Wainwright restating a "buy" rating. The company has a market capitalization of $49.95 million and reported ($0.06) earnings per share for the quarter, topping analysts' estimates. Oncolytics Biotech is developing pelareorep, an immunotherapeutic agent, for the treatment of cancer. The stock opened at $0.58 on Tuesday, with a 50-day simple moving average of $0.49 and a 200-day simple moving average of $0.67.
June 13, 2025 • By MarketBeat News
Mersana Therapeutics (NASDAQ:MRSN) has been given an average rating of "Buy" by 7 analysts, with a 12-month target price of $5.20. Recently, several research analysts issued reports on MRSN shares, including Guggenheim, Truist Financial, William Blair, and Wedbush, with most reaffirming "buy" or "outperform" ratings. The company reported a quarterly loss of $0.19 per share, topping estimates, and had revenue of $2.75 million. Analysts predict a loss of $0.62 per share for the current year. Mersana Therapeutics is a clinical-stage biopharmaceutical company developing antibody drug conjugates for cancer patients.
June 13, 2025 • By Avextra Pharma GmbH
A recent study, CORAL, found significant symptom relief for late-stage palliative patients treated with cannabis-based medicines. The study, led by Prof. Dr. med. Sven Gottschling, involved 150 patients, with 100 receiving the cannabis extract Avextra 10:10 and 50 receiving non-cannabinoid treatment. Results showed improved quality of life and reduced symptom burden. Avextra, a leading European medical cannabis operator, collaborated on the study and aims to develop innovative dosage forms for palliative care patients. The company will continue conducting studies to explore the clinical outcomes of cannabis-based medicines.
June 13, 2025 • By Bill Anderson
The CEO of Bayer, Bill Anderson, argues that Europe is losing ground in innovation, particularly in the life sciences industry, to the US and China. He cites the decline in new medicines originating from Europe, from 50% in the 1990s to 20% today. Anderson attributes this decline to excessive regulation, which hinders the growth of startups and innovation. He suggests that Europe needs to simplify its regulatory environment, invest in research and development, and provide robust IP protection to attract high-risk investors. Anderson also emphasizes the need for a "distinctly European course correction" to unleash the continent's innovative spirit, rather than trying to replicate the US model. He believes that with the right mindset and conditions, Europe can produce world-changing innovation and become a hub for biotech and life sciences.
June 13, 2025 • By Paul McClure
A Phase 3 clinical trial has found that a new, long-acting, once-weekly pill for schizophrenia symptoms is as effective as the existing daily treatment. The pill, a version of the antipsychotic medication risperidone, works by balancing dopamine and serotonin levels in the brain. The trial compared the new pill, developed by Lyndra Therapeutics, to the daily version and found that both produced comparable therapeutic effects. The new pill could simplify patient care and improve medication adherence without compromising effectiveness. The trial enrolled 83 participants with schizophrenia or schizoaffective disorder and found that the new pill maintained steady blood risperidone concentrations similar to the daily version. Side effects were common but mostly mild to moderate. The study's results offer a novel long-acting oral drug delivery technology for schizophrenia and schizoaffective disorder, and could enhance patient autonomy and medication adherence.
June 12, 2025 • By Foreign, Commonwealth & Development Office
The UK Foreign Secretary delivered a speech discussing the concept of power in the modern world, highlighting the impact of technology on geopolitics. The Secretary noted that China is a significant technological power, but the US remains the world's leading technological power. The speech emphasized the importance of cooperation and alliances in addressing global challenges, introducing the concept of "progressive realism." This approach prioritizes cooperation, listening, and pragmatism in international relations. The Foreign Secretary announced several initiatives, including a Countering Illicit Finance Summit in London to tackle dirty money and kleptocracy. The UK will also increase defense spending to 2.6% of GDP by 2027 and establish a new counter-hybrid taskforce to address emerging security threats. The speech touched on various global issues, such as the conflict in Gaza, the importance of a two-state solution, and the need for cooperation on irregular migration. The Foreign Secretary emphasized the UK's commitment to working with international partners to address these challenges and promote a more stable and prosperous world. Overall, the speech outlined the UK's approach to international relations, emphasizing the need for cooperation, pragmatism, and a commitment to progressive values in addressing the complex challenges of the modern world.
June 12, 2025 • By fiercebiotech.com
BioNTech has acquired German mRNA vaccine peer CureVac in a $1.2 billion all-stock deal. The acquisition brings together two major players in the mRNA vaccine space, with BioNTech being the developer of the COVID-19 vaccine Comirnaty. The deal is expected to expand BioNTech's capabilities and portfolio in the mRNA vaccine market.
June 12, 2025 • By bizjournals.com
Chicago's life-sciences ambitions are facing challenges due to federal funding cuts for research. Northwestern University has announced a hiring freeze, and other top institutions are tightening their budgets. The reduction in funding from the National Institutes of Health (NIH) is forcing these institutions to reevaluate their priorities and make difficult financial decisions. This development threatens Chicago's biotech ambitions and may have long-term implications for the city's life-sciences industry.